Scholar Rock Holding Gestione

Gestione criteri di controllo 3/4

Scholar Rock Holding Il CEO è Jay Backstrom, nominato in Oct2022, e ha un mandato di 2.08 anni. la retribuzione annua totale è $ 4.11M, composta da 15.2% di stipendio e 84.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.028% delle azioni della società, per un valore di € 743.72K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 7.7 anni.

Informazioni chiave

Jay Backstrom

Amministratore delegato

US$4.1m

Compenso totale

Percentuale dello stipendio del CEO	15.2%
Mandato del CEO	2.1yrs
Proprietà del CEO	0.03%
Durata media del management	2.1yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jay Backstrom rispetto agli utili di Scholar Rock Holding?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$226m
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$183m
Dec 31 2023	US$4m	US$624k	-US$166m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$7m	US$159k	-US$135m

Compensazione vs Mercato: La retribuzione totale di Jay ($USD 4.11M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.90M ).

Compensazione vs guadagni: La retribuzione di Jay è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jay Backstrom (69 yo)

2.1yrs

Mandato

US$4,111,853

Compensazione

Dr. Jay Thomas Backstrom, M.D., M.P.H., serves as Non-Executive Director of LAVA Therapeutics N.V. since June 2022. He serves as Director at Be Biopharma, Inc. since December 2021. He had served as a Direc...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jay Backstrom	President	2.1yrs	US$4.11m	0.028% € 743.7k
Edward Myles	CFO, COO & Treasurer	4.3yrs	US$2.01m	0% € 0
Tracey Sacco	Chief Commercial Officer	1.8yrs	US$2.28m	0% € 0
Mo Qatanani	Chief Scientific Officer	less than a year	Nessun dato	0.022% € 580.5k
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	Nessun dato	Nessun dato
Junlin Ho	General Counsel & Corporate Secretary	4.7yrs	US$2.13m	0.079% € 2.1m
Caryn Parlavecchio	Chief Human Resources Officer	3.3yrs	Nessun dato	0.043% € 1.1m
Lisa Price	Senior Vice President of Human Resources	no data	Nessun dato	Nessun dato
Erin Moore	Senior Vice President of Finance	no data	Nessun dato	Nessun dato
Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	4.7yrs	Nessun dato	Nessun dato
Jing Marantz	Chief Medical Officer	2yrs	Nessun dato	0.078% € 2.1m
Beth Shafer	Chief Business Officer	less than a year	Nessun dato	Nessun dato

2.1yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di 2QK è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jay Backstrom	President	2.1yrs	US$4.11m	0.028% € 743.7k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	11yrs	US$299.20k	0.040% € 1.1m
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	Nessun dato
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	8.1yrs	US$305.70k	0.033% € 898.9k
Leonard Zon	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Daniel Rifkin	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Kristina Burow	Independent Director	10.3yrs	US$300.34k	0.0057% € 153.3k
Joan Massague	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
David Hallal	Independent Chairman of the Board	7.3yrs	US$416.70k	0.31% € 8.3m
Scott L. Friedman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Barry Coller	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Joshua Reed	Independent Director	3.7yrs	US$305.70k	0% € 0

7.7yrs

Durata media

69yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2QK sono considerati esperti (durata media dell'incarico 7.7 anni).

Scholar Rock Holding Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Senior VP & Head of Research recently sold €268k worth of stock

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

New major risk - Financial position

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Senior VP & Head of Research recently sold €268k worth of stock

New major risk - Revenue and earnings growth

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021)

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock Announces Chief Executive Officer Changes

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Scholar Rock Holding Corporation Provides Pipeline Updates

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Forecast to breakeven in 2025

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019)

Revenue misses expectations

New 90-day high: €50.00

Scholar Rock Announces Executive Promotions

New 90-day high: €47.40

New 90-day high: €43.80

Third quarter 2020 earnings released: US$0.79 loss per share

Revenue misses expectations

New 90-day high: €31.80

Earnings released

Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020

Scholar Rock Holding Corporation Announces Executive Changes, Effective August 1, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione